| Bioactivity | Gefitinib (ZD1839) (GMP) is Gefitinib (HY-50895) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. Gefitinib is a potent, selective and orally active EGFR tyrosine kinase inhibitor[1][2]. |
| Invitro | Gefitinib (GMP) abolishes the effect of EGF-induced dedifferentiation of astrocytes into astrocyte precursor cells (APCs)[2].Gefitinib (3 μM) can produce a subgroup of EGFR-mutant NSCLC cell lines (Gefitinib-resistant cells) that undergo cellular reprogramming, such as HCC827 cells[3]. |
| Name | Gefitinib (GMP) |
| CAS | 184475-35-2 |
| Formula | C22H24ClFN4O3 |
| Molar Mass | 446.90 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
Gefitinib (GMP)
CAS: 184475-35-2 F: C22H24ClFN4O3 W: 446.90
Gefitinib (ZD1839) (GMP) is Gefitinib (HY-50895) produced by using GMP guidelines. GMP small molecules work appropriatel
Data collection：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.